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Abstract 
Parkinson's disease is a non-treatable neurological disorder that can 
lead to an inability to control one’s own muscles, causing rigidness and 
lack of movement. α-Synuclein is a protein that has been found in 
aggregate forms in PD patients and seems to bind to synaptic vesicle 
membranes and aid in vesicle transporting. This research focuses on 
the effect that over-expressed forms of α-synuclein have on 
presynaptic terminals of C. elegans. To examine this relationship we 
constructed transgenic animals expressing α-synuclein throughout the 
nervous system of wild type C. elegans. The α-synuclein strain had 
disruption of the puncta along the axon compared to non over-
expressed α-synuclein strain, suggesting that the disruption taking 
place in the synaptic terminals is caused by the presence of α-
synuclein. Such disruption in active zone organization causes a loss of 
neuron signaling, resulting in symptoms similar to those observed in 
Parkinson's disease patients.	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Introduction 
 
Neurodegenerative disease 
 The human body is made up of trillions of cells; the preservation 
of many of those cells depends on the ability for them to be repaired 
or replaced at a continuous rate. Unfortunately cells that make up the 
central nervous system don't have the ability to simply replace 
damaged cells; when those cells are impaired there is no process that 
can repair them. Neurodegenerative diseases are a group of disorders 
that are caused by death or deterioration of neurons in the central 
nervous system resulting in permanent damage. The nature of 
neurodegenerative diseases make these diseases extremely hard to 
treat and because many are related to genetic defects, they are 
equally as hard to prevent. Diseases in this category include 
Alzheimer's disease, Parkinson's disease (PD), Amyotrophic Lateral 
Sclerosis (ALS or Lou Gehrig's disease), Huntington's disease, Multiple 
Sclerosis, and Creutzfeldt-Jacob disease. The presence of a unique 
protein is a shared feature among neurodegenerative diseases and in 
nearly all cases that specific protein goes through some form of 
misfolding, aggregation, and/or accumulation in the brain of patients 
(Taylor, Hardy, & Fischbeck., 2002). If misfolding occurs it can 
negatively affect the function of the protein by either producing 
harmful products or not producing necessary products. When protein 
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dysfunction occurs it generally results in new toxic functions, leading 
to neurodegenerative diseases if not handled by the regulatory 
processes of the cell. One of the most studied neurodegenerative 
diseases is PD, and while there is much research ongoing, it still 
remains difficult to understand all of its complex mechanisms. 
PD 
 PD affects approximately seven to ten million people worldwide, 
including nearly one million patients in the United States alone making 
it more prevalent then multiple sclerosis, muscular dystrophy, and Lou 
Gehrig's disease combined (PD Foundation, 2014). The treatment of 
PD leads to an estimated health care expense of 25 billion dollars 
annually in the United States (PD Foundation, 2014). PD causes 
neuronal degeneration and an inability to control one’s own muscles, 
as well as loss of mental cognition. This can ultimately lead to tremors 
at rest, rigidity, slowness, absence of voluntary movement, postural 
instability, and freezing (Dauer & Prezdborski, 2003). Cognitive 
behaviors such as a passive or withdrawn personality, lack of initiative, 
delayed question response, depression, and increased frequency of 
dementia have been observed as well (Dauer & Prezdborski, 2003). 
Several of PD's symptoms can be alleviated through the use of the 
dopamine (DA) precursor Levodopa (L-3,4-dihydroxyphenylalanine), 
although when administered routinely the symptoms returned after 
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several years (Dauer & Prezdborski, 2003). There is currently no 
treatment that can completely rid patients of PD. 
 An indication of PD is the post mortem observation of Lewy 
bodies, spherical eosinophilic cytoplasmic protein aggregates 
composed of numerous proteins, in substantia negra pars compacta 
(SNpc) dopaminergic neurons (Dauer & Prezdborski, 2003). Lewy 
bodies are comprised of several proteins including α-synuclein, parkin, 
ubiquitin, and neurofilament (Forno, 1996; Spillantini, Crowther, 
Jakes, Hasegawa, & Goedert, 1998). Although little is understood of 
the function of these Lewy bodies, some evidence depicts them as an 
active process to sequester soluble misfolded proteins from the cellular 
milieu (Kopito, 2000).  The onset of PD is more common in adults near 
sixty years old, but can occur at any age (Nass & Przedborski, 2008). 
The elderly are more at risk because as a human ages, the ability of 
cells to induce a variety of chaperones to handle misfolded protein and 
the activity of proteasome are impaired (Dauer & Prezdborski, 2003). 
A key function of chaperone proteins and proteasomes is to target and 
degrade these damaged proteins involved with PD, stopping any toxic 
function they may cause. 
 PD is characterized by the degeneration of dopaminergic neurons 
in the SNpc and the loss of motor function. Dopaminergic neurons 
support the release of the neurotransmitter dopamine, exciting the 
striatal neurons, which aid in controlling the ventroanterior and 
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ventrolateral nuclei of the thalamus, affecting movement. Once PD 
causes enough degeneration of the dopaminergic neurons this leads to 
dopamine reduction as seen in Figure 1, ultimately limiting muscle 
control. 
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Figure 1: PD pathway. The left side shows the normal mechanism of 
dopamine release from the presynaptic terminal. The right side 
demonstrates possible outcomes that can arise in the presynaptic 
terminal, preventing correct dopamine release and causing PD in 
humans (Shen, 2012). 
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 There are two main forms of PD, sporadic, caused by 
environmental factors, and familial, caused by genetic factors such as 
inheritance or mutations. An important discovery is that even though 
these forms arise in different ways, both have been shown to be 
associated with α-synuclein. Although there are several newly found 
forms of PD, they are less common and not understood as well. 
Sporadic PD is involved in an estimated 85 to 90 percent of cases 
(Fahn, 2008). It is thought to be caused by the misfolding and 
aggregation of the α-synuclein protein, mitochondrial dysfunction 
leading to oxidative stress,  as well as certain chemicals or toxins 
(Dauer & Prezdborski, 2003). The chemical MPTP (1-Methyl-4-phenyl-
1,2,5,6-tetrahydropyridine) was discovered to cause PD symptoms; it 
was originally found in synthetic heroin (Langston et al., 1983); other 
chemicals include pesticides (Betarbet et al., 2000), heavy metals 
(Calne et al., 1994), and free radicals (Maguire-Zeiss et al., 2005).  
These environmental factors can start a chain reaction of deleterious 
events resulting in a loss of dopaminergic neurons in the SNpc. An 
example of this cascade is the disruption of normal metabolism, which 
is caused by mitochondrial dysfunction leading to the creation of 
reactive oxygen species thus causing further mitochondrial 
dysfunction.  
 The familial form of PD has been classified through a number of 
point mutations in the α-synuclein gene and other genes leading to 
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similar effects. There are nine commonly identified genetic mutations 
that can result in PD; three of them are point mutations on the α-
synuclein (SNCA) gene itself and the rest are related to six additional 
genes. The mutations identified on the SNCA gene are A30P 
(Polymeropoulos et al., 1997), A53T and E46K (Zarranz et al., 2009). 
The A30P mutation, discovered in a German family, has a proline 
instead of an alanine amino acid at the 30th codon position 
(Polymeropoulos et al., 1997). The A53T mutation, discovered in an 
Italian-American Greek family, has a threonine instead of an alanine 
amino acid at the 53rd codon position (Kruger et al., 1998). The E46K 
mutation, discovered in a Spanish family, has a lysine instead of a 
glutamic acid amino acid at the 46th codon position (Zarranz et al., 
2004). An increased understanding of specific folding changes 
associated with these mutations, may provide a solution for α-
synuclein misfolding. Unfortunately the changes in the proteins 
produced from these mutations appear to be a much harder problem 
to resolve, although studying the other genes associated with PD can 
be useful. 
 These other genes include, Parkin (Kitada et al., 1998), UCH-L1 
(Liu et al., 2002), DJ-1 (Bonifati et al., 2003), PINK1 (Valente et al., 
2004), LRRK2 (Funayama et al., 2002), and PARK9 (Ramirez et al., 
2006). The Parkin and UCH-L1 genes identified can interfere with the 
ubiquitin proteasome system (Kitada et al., 1998; Liu et al., 2002). 
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The DJ-1 gene has been shown to be involved through its response to 
oxidative stress (Bonifati et al., 2003). The PINK1 and LRRK2 gene 
products cause phosphorylation in mitochondria in response to 
dysfunction and in α-synuclein respectively (Valente et al., 2004; 
Funayama et al., 2002). The last related gene PARK9 aids in protecting 
cells from manganese toxicity and if mutated or lost can cause 
degradation dysfunction (Ramirez et al., 2006). These genes have 
important functions related to either degrading proteins or the removal 
of harmful products; both are key features shown to cause PD. A 
shared thread in both sporadic and familial cases of PD is the 
involvement of α-synuclein, whether from the aggregation tendency in 
sporadic forms or the gene mutation effect in familial forms.  α-
Synuclein still needs to be examined to fully determine its role in the 
PD pathology. 
  
α-Synuclein 
 The SNCA gene is located at q22.1 of the 4th chromosome in 
humans and encodes the α-synuclein protein that is responsible for 
both sporadic and familial cases of PD. α-Synuclein is a 140 amino acid 
protein that remains natively unfolded in vitro (Bertoncini et al., 2005; 
Weinreb et al., 1996), although it appears as α, β, and γ structures, 
notably forming its α-helix upon binding to artificial membranes 
(Davidson et al., 1998). Although α-synuclein's function is unclear, it 
appears to be involved in aiding vesicle trafficking (Cooper et al., 
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2006), neurotransmitter release (Jensen et al., 1998; Cabin et al., 
2002), and maintaining synaptic plasticity through actin regulation 
(Bellani et al., 2010). The N terminus of α-synuclein is composed of an 
11 residue repeat that forms an amphipathic α-helix protein structure; 
these repeats are highly conserved among the various spliced isoforms 
and across species (Bendor et al., 2013). In contrast the C terminus of 
α-synuclein is not as conserved across species. Additionally the C 
terminus is polar and undergoes phosphorylation at multiple sites 
(Oueslati et al., 2010; Sato et al., 2013). The protein is primarily 
found in presynaptic terminals within the olfactory bulbs, cerebral 
cortex, hippocampus, and substantia nigra (Kaplan et al., 2003). It 
has also been associated with synaptic vesicles, localized to the nerve 
terminal, with relatively little in the cell body, dendrites, or extra 
synaptic sites along the axon (George et al., 1995; Iwai et al., 1995).   
α-Synuclein in misfolding and aggregation 
 One of the processes through which α-synuclein can cause PD in 
patients is through its misfolding, leading to aggregation. In this 
instance, α-synuclein forms oligomers, which are stabilized into an 
insoluble β-sheet isoform and form Lewy bodies as seen in Figure 2. 
These Lewy bodies are commonly recognized in PD as well as 
Alzheimer's and Dementia with Lewy bodies patients. Misfolding of α-
synuclein can take place simply by over-expressing it, which can 
happen naturally in the case of gene multiplication (Ahn et al., 2008; 
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Singleton et al., 2003). Several studies have shown that increasing the 
amount of α-synuclein increases its tendency to misfold and produce 
Lewy bodies. While the accumulation of these Lewy bodies seem to be 
present in PD patients, it also appears that the formation of Lewy 
bodies is a protective mechanism that prevents damaged or misfolded 
proteins from performing harmful actions (Volles, 2002). Normally 
clumping up these damaged proteins can limit their expression and aid 
in marking them for degradation. The problem with these Lewy bodies 
is that they complicate the degradation process generally carried out 
by the ubiquitin-proteasome system as well as by lysosomes. Instead 
of degrading misfolded proteins in cells, the Lewy bodies are very 
difficult to transport and their insoluble nature makes it equally as 
difficult to be degraded like typical proteins.  
 Cells regularly need to recycle misfolded proteins, without this 
regulation diseases such as Atherosclerosis, Cancer, Congenital 
Hypothyroidism, Cystic Fibrosis, Diabetes, Fatty Liver disease, 
Hemophilia, Polycystic Kidney disease, and Alzheimer's disease can 
occur (Pobojewski, 2010). The method by which the ubiquitin 
proteasome system recycles proteins is by attaching the small protein 
ubiquitin to the protein that needs to be degraded; this targets the 
molecule for the proteasome to recycle as illustrated in Figure 3. Some 
evidence has shown that ubiquitin is required for α-synuclein 
degradation; both the Parkin and UCH-L1 mutation appear to 
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hydrolyze ubiquitin resulting in a greater presence of aggregate α-
synuclein (Liu et al, 2002). Through the use of lysosomes cells can 
recycle proteins from the plasma membrane and from outside of the 
cell. This process occurs in one of three ways: phagocytosis, 
autophagy and endocytosis. In phagocytosis the cell engulfs the 
molecules identified for degradation. In autophagy a membrane 
surrounds the marked molecule then sends it to the lysosome for 
degradation. Finally, in endocytosis the membrane buds, forming an 
endosome, which is transported to the lysosome for degradation.  
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Figure 2: α-Synuclein aggregation pathway. The left side of the 
diagram shows α-Synuclein misfolding into an oligomer then 
aggregating until a Lewy body is formed. In the right side of the 
diagram, toxic stress of these Lewy bodies can result in decreased 
synaptic vesicle release and energy production impairment. (Cookson, 
2009) 
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Figure 3: Lysosome/Proteasome degradation pathway. Left side, 
the process of lysosomes degrading cellular products and forming 
phagolysomes when degrading damaged mitochondria. Right side, the 
process of proteasomes degrading targeted proteins (Adams, 2004). 
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α-Synuclein in membrane interactions 
 An important feature of α-synuclein is its preference to bind to 
membranes with high curvatures, this is due to the hydrophobic face 
of the N-terminal containing threonine (Jensen et al., 2011; Middleton, 
2010). The high curvature attraction explains its localization to 
synaptic vesicles which are among the smallest vesicles. This can also 
explain the other way α-synuclein can cause PD: mitochondrial 
dysfunction and oxidative stress. Normal mitochondrial function is 
shown in Figure 4, but mitochondrial dysfunction leads to the 
production of reactive oxygen species (ROS); these include 
superoxide, hydrogen peroxide, and the hydroxyl radical (Abou-
Sleiman, Muqit, & Wood, 2006).  As ROS are released within the cells 
they damage structures and lipid membranes through lipid 
peroxidation (Lenaz, 1998). At the same time ROS affects metabolic 
functions which can lead to further mutation in mitochondrial DNA, 
causing increased toxicity. Other experiments have shown α-synuclein 
can disrupt mitochondrial membranes by inhibiting membrane fusion 
in vitro (Kamp et al., 2010). α-Synuclein inhibits membrane fusion by 
binding to a fusion stalk, stopping the packing stress needed to carry 
out membrane fusion (Figure 5). Due to the common localization of 
mitochondria and synaptic vesicles, at the presynaptic terminals, over-
expression of α-synuclein causes it to associate more with 
mitochondrial membranes (Kamp et al., 2010). This in turn leads to 
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fragmented mitochondrial membranes resulting in dysfunction and 
ROS production.  
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Figure 4: Mitochondrial Pathway. Diagram showing the standard 
function of mitochondria, cycles into various products until providing 
useable energy. The cycle includes oxidative molecules that could 
result in harmful products if not managed correctly (Neuromuscular 
Disease Center, 2014). 
 
 
 
Figure 5: Membrane Fusion Stalk Process. Step A, the normal 
bending and fusion of membranes, creating a fusion stalk. Step B, the 
introduction of α-synuclein caps the high curvature membrane 
preventing the formation of the fusion stalk (Kamp, 2010). 
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C. elegans as a model organism 
 Model organisms are used in order to progress research further 
and faster then human trials could possibly achieve. Caenorhabditis 
elegans (C. elegans) is a very effective and well used model organism 
to study various biological processes including mutations found on the 
α-synuclein gene such as Ser-129 (Kuwahara, 2012). C. elegans can 
be studied in place of humans because evolution has conserved many 
of the metabolic and developmental pathways across species (Kaletta, 
2006). The other major advantage for researchers is that model 
organisms such as C. elegans don't spark the same ethical debates as 
humans or higher level organism experiments. 
 C. elegans are non-parasitic transparent nematodes; they 
generally live in temperate soil environments and grow to a length of 
one mm, as shown in Figure 6. C. elegans has five pairs of autosomal 
chromosomes and one pair of sex chromosomes; The benefits of C. 
elegans include the ease in maintaining, using agar plates with E. coli 
as their food source. In addition, a single worm can lay between 300 
to 1000 eggs, which allows lethal experiments to be performed on 
them as long as some offspring can survive. C. elegans are able to 
reproduce after 3 to 4 days in optimal conditions and go through 
several life stages in that time, shown in Figure 7. The fast generation 
times of these organisms allow researchers to get results much quicker 
than using many other multicellular eukaryotes. Since C. elegans is a 
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relatively simple organism and has been a staple in biological study, it 
has had it's entire genome sequenced and it's available for anyone to 
access. A sample of the wild type strain used in this experiment can be 
seen in Figure 8. 
 Another benefit to using C. elegans is that they are generally 
hermaphrodites and can self inseminate to produce their offspring.The 
hermaphrodites possess sex chromosomes of XX and males possess 
sex chromosomes of a single X for males. When they reproduce they 
pass on all of their genes to their hermaphrodite offspring; this makes 
mutant genes easy to maintain. Although hermaprodites are very 
useful, some experiments require males in order to create double 
mutants. C. elegans are able to produce males; males arise through 
either stressful environments or having a male worm inseminate a 
hermaphrodite; this is used as a way of creating double mutants or 
performing complementation tests. Male C. elegans look nearly 
identical to hermaphrodites except they have a bulb shape on their tail 
and no female reproductive organisms. A negative consequence to 
hermaphordite offspring is it takes more time to maintain male forms 
with mutant genes; they are generally preserved in their 
hermaphrodite sex until a male mutant is needed for experiments. 
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Figure 6: Anatomy of C. elegans hermaphrodite. A layout of the 
anatomy of an adult hermaphrodite C. elegans, the sperm cells can 
meet the eggs inside the worm for self fertilization (Caenorhabditis 
elegans, 2014). 
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Figure 7: C. elegans life stages. The different stages of C. elegans 
are defined as egg, L1, (Dauer), L2, L3, L4, young adult, and adult 
(adult with eggs). The life cycle generally takes 3 to 4 days, but if 
worms are starved they enter the Dauer stage which they become 
skinny, require no food, and can survive for extended periods of time 
(Introduction to C. elegans Anatomy, 2013). 
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Figure 8: Microscopic view of wild type C. elegans. N2 strain was 
photographed 3 days after transferring to a seeded plate containing E. 
coli.    
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Gene markers 
 Several mutants were created in order to track movement and 
visualize synaptic vesicles, mitochondria, and lysosomes. Each of the 
created genes contained a green fluorescent protein (GFP) as a 
reporter, and mCherry, red fluorescent protein, as a marker of their 
respective cellular element, synaptic vesicles, mitochondria, or 
lysosomes. Rab-3 is a gene located on chromosome 2, position 
5721769 of C. elegans, and encodes a rab3 homolog. This is a Ras 
GTPase that affects the distribution of synaptic vesicles and synaptic 
transmission; it is generally found in synapse rich regions in axons 
(Wormbase, 2014). Tomm-20 is a gene located on chromosome 5, 
position 12342310 of C. elegans, and encodes for a TOM20 homolog. 
This is a mitochondrial subunit coding for a translocase of the outer 
mitochondrial membrane (Wormbase, 2014). The function of this 
translocase is to allow proteins through the mitochondrial membrane 
into the inner membrane region (Perry, 2008). Ctns-1 is a gene 
located on chromosome 2, position 8134757 of C. elegans, and 
encodes for an ortholog of the human cystinosin gene, a lysosomal 
cystine transporter. This is required for transport of hydrolytic 
degradation products from lysosomes and the transport of cystine 
from lysosomes (Wormbase, 2014). The pathway the mutant strains 
were testing for can be seen in Figure 9. 
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Figure 9: Protein misfolding pathways. Model of α-synuclein 
defects leading to PD. Red arrows indicate hypotheses of this research, 
black arrows indicate continued theories. Arrow A is tested with the 
rab-3 marker on synaptic vesicles, Arrow B is tested with the tomm-20 
marker on mitochondrial membranes, and Arrow C is tested with the 
ctns-1 marker for lysosome waste transport (Dauer & Prezdborski, 
2003). 
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Hypotheses and aims 
 
 The aim of this study was to over-express α-synuclein to 
determine if it affects the synaptic vesicles. I predicted that this over-
expression of α-synuclein would cause aggregation of the synaptic 
vesicles, present as Lewy Bodies.   
 Hypothesis 1: Over-expression of α-synuclein in C. elegans 
neurons will affect the localization of synaptic vesicles at the active 
zones of the presynaptic terminals.  
 The aim of this study was to over-express α-synuclein in order to 
learn how it affects mitochondria, which in turn may produce oxidative 
stress. I predicted that this over-expression of α-synuclein would 
inhibit fusion of the mitochondrial membrane leading to reactive 
oxygen species.  
 Hypothesis 2: Over-expression of α-synuclein in C. elegans 
neurons will affect the formation of mitochondrial membranes at the 
active zones of the presynaptic terminals.   
 The aim of this study was to over-express α-synuclein so that 
any disruption of lysosomal membranes can be observed, possibly 
leading to protein degradation problems. I predicted that this over-
expression of α-synuclein would similarly inhibit fusion of lysosomal 
25 
	  
membranes, so that protein aggregates remained instead of being 
degraded.  
 Hypothesis 3: Over-expression of α-synuclein in C. elegans 
neurons will affect the formation of lysosomal membranes leading to 
transport and degradation problems at the active zones of the 
presynaptic terminals.   
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Results 
 
 Each gene plasmid, rab-3, tomm-20, and ctns-1, was made 
through the cloning of E. coli and verified by length through PCR, 
restriction enzyme digestion, and gel electrophoresis. Several 
restriction enzymes were used due to multiple restriction sites within 
the genes themselves, until a sufficient length product was observed. 
Each mutant was then mated with a strain over-expressing α-synuclein 
and signified through the nomenclature, *α-synuclein. 
Experimental design for aim 1 
 The first hypothesis was that over-expression of an α-synuclein 
gene in C. elegans neurons would affect the localization of synaptic 
vesicles at the active zones of the presynaptic terminals. The initial 
experiment was performed to determine the effect on the localization 
of synaptic vesicles by creating the rab-3 mutant and rab-3*α-
synuclein mutant and analyze their movement. This was an essential 
test since changes in synaptic vesicle localization would affect how the 
synaptic terminals function. I predict that altering synaptic terminals 
would affect the normal movement of the C. elegans mutants. 
 The second experiment to analyze the localization of synaptic 
vesicles was to use a fluorescent microscope with a camera to 
visualize the synaptic vesicles along the axon for both the rab-3 and 
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rab-3*α-synuclein mutants. These mutants were compared in a 
qualitative manner through fluorescent microscopy. The spacing and 
brightness of the fluorescent markers were described as well as 
recognition of clumping. The hypothesis is that since the rab-3 marker 
is used to visualize synaptic vesicle position, this data would aid in 
determining any localization differences. 
Movement tracking of rab-3 and rab-3*α-synuclein mutants 
 In order to track the movement and allow a proper comparison 
of both mutants, they needed to be recorded at the same time. Figure 
10 shows an image of the mutant strain set up for tracking their 
movement. A picture of the worms was taken every 500ms and their 
position, center of the worm, was recorded, each position difference 
was used to convert to velocity. The velocity data was graphed 
comparing the mutants, shown in Figures 11 and 12. The result 
showed that the N2 average velocity was 161.06±18.79µm/s and the 
α-synuclein average velocity was 98.42±27.20µm/s. This showed a 
significant difference in the average velocity between the N2 and α-
synuclein strains (T-test= 3.1412, p-value= 0.0051, df=20). The 
graph in Figure 12 shows the average velocity of the rab-3 and rab-
3*α-synuclein mutants. The result showed that the rab-3 average 
velocity was 98.60±11.87µm/s and the rab-3*α-synuclein average 
velocity was 107.95±9.74µm/s. This showed no significant difference 
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in the average velocity between the rab-3 and rab-3*α-synuclein 
strains (T-test= 1.0543, p-value= 0.3032, df=22). 
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Figure 10: Rab-3*α-synuclein tracking. Rab-3 (right) and Rab-
3*α-synuclein (left) movement tracking experiment. Image captured 
using a Go-3 digital camera on a light microscope at 6.3x 
magnification. 
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 Figure 11: Average velocity comparison graph of N2 and α-
Synuclein C. elegans strains. T-test= 3.1412, P-value= 0.0051, 
df=20. Average velocity showed significant difference between the 
strains. Data collected using Image Pro Plus, and a series of 120 
pictures at 500ms per picture, graphed through Excel. 
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Figure 12: Average velocity comparison graph of Rab-3 and 
Rab-3*α-Synuclein C. elegans strains. T-test= 1.0543, P-value= 
0.3032, df=22. Average velocity showing no significant difference 
between the strains. Data collected using Image Pro Plus, and a series 
of 120 pictures at 500ms per picture, graphed through Excel. 
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Fluorescent imaging and quantification of rab-3 and rab-3*α-
synuclein mutants 
 The C. elegans strains rab-3 and rab-3*α-synuclein were both 
mounted onto agar pads on microscope slides. From there they were 
observed through a fluorescent microscope with a camera attached in 
order to capture the images. Several pictures of both strains were 
taken, looking for correct worm body orientation in order to clearly 
visualize the axon terminal. The pictures were taken showing the red 
fluorescence of the rab-3 marker along the axon terminal, the strains 
were then compared at 630x magnification, shown in Figure 13. On a 
consistent basis the markers of the rab-3*α-synuclein strain appeared 
less frequently and were dimmer then the rab-3 strain not expressing 
α-synuclein.  
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A
B
C
D 
Figure 13: Axon Terminals of C. elegans. Images Α-D show rab-3 
marker expression. Red florescent markers represent active zones of 
the synaptic vesicles. (Α-D) The axon terminals of wild type rab-3 
animals, overall showing high puncta frequency and signal strength.  
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E
F
G
H 
Figure 13 (continued): Axon Terminals of C. elegans. Images E-
H show rab-3 marker expression. Red florescent markers represent 
active zones of the synaptic vesicles. (E-H) The axon terminals of rab-
3*α-synuclein animals, overall showing low puncta frequency and 
signal strength. 
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Experimental design for aim 2 
 The second hypothesis was that over-expression of an α-
synuclein gene in C. elegans neurons would affect the formation of 
mitochondrial membrane at the active zones of the presynaptic 
terminals. The experiment to determine any affect on the 
mitochondrial membrane formation was to create the tomm-20 mutant 
along with the tomm-20*α-synuclein mutant and analyze their 
movement. This was essential test because mitochondria provide the 
energy needed for cells to carry out their function and the effect of 
dysfunction in the active zones of the presynaptic terminals would 
appear to alter it. Since tomm-20 encodes for protein associated with 
the mitochondrial membrane, if it's production is impaired this could 
cause cell death and release of ROS. This lead to the hypothesis that 
mitochondrial dysfunction may produce reactive oxygen species at the 
presynaptic terminal and would affect the normal movement of the C. 
elegans mutants. 
Movement tracking of tomm-20 and tomm-20*α-synuclein 
mutants 
 Both the tomm-20 and tomm-20*α-synuclein mutants were 
observed at the same time to eliminate other variables that may affect 
the experiment. Figure 14 shows an image of the mutant strain set up 
for tracking their movement. The velocity data was graphed comparing 
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the mutants, shown in Figure 15. The result showed that the tomm-20 
average velocity was 145.95±18.97µm/s and the tomm-20*α-
synuclein average velocity was 152.11±15.79µm/s. This showed no 
significant difference in the average velocity between the tomm-20 
and tomm-20*α-synuclein strains (T-test= 0.424, P-value= 0.6759, 
df= 21). 
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Figure 14: Tomm-20*α-synuclein tracking. Tomm-20 (left) and 
Tomm-20*α-synuclein (right) movement tracking experiment. Image 
captured using a Go-3 digital camera on a light microscope at 6.3x 
magnification. 
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 Figure 15: Average velocity comparison graph of Tomm-20 and 
Tomm-20*α-Synuclein C. elegans strains. T-test= 0.424, P-
value= 0.6759, df= 21. Average velocity showing no significant 
difference between the strains. Data collected using Image Pro Plus, 
and a series of 120 pictures at 500ms per picture, graphed through 
Excel. 
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Fluorescent imaging and quantification of tomm-20 and tomm-
20*α-synuclein mutants 
 The images in Figure 16 were attempting to show the difference 
in the mitochondrial membranes between the tomm-20 mutant and 
tomm-20*α-synuclein mutant at 630x magnification. The images were 
unclear and difficult to visualize the location of the mitochondria. There 
was no discernible difference between the mutants in any of the 
pictures taken.  
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   A         B 
  
    C         D 
 
Figure 16: Tomm-20 fluorescence in C. elegans. Images A-D 
show tomm-20 marker expression. White florescence represents 
production of the translocase of the outer mitochondrial membrane. No 
noticeable difference among the wild type and mutant fluorescence. 
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   E         F   
  
   G         H 
   
Figure 16 continued: Tomm-20 fluorescence in C. elegans. 
Images E-H show tomm-20 marker expression. White florescence 
represents production of the translocase of the outer mitochondrial 
membrane. No noticeable difference among the wild type and mutant 
fluorescence. 
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Experimental design for aim 3 
 The third hypothesis was that over-expression of an α-synuclein 
gene in C. elegans neurons will affect ability of the lysosomes to 
properly transport and degrade aggregates in the synaptic terminal. 
The opening step to determine any affect on the lysosomes ability to 
transport and degraded proteins was by creating the ctns-1 mutant 
along with the ctns-1*α-synuclein mutant and analyze their 
movement. Ctns-1 is useful since it encodes for a cystine transporter, 
which aids the in the transport of cystine and lysosomal degradation 
products. This was necessary test since the accumulation of 
aggregates in the synaptic terminal reduce the ability of the active 
zones to release neurotransmitters. This lead to the hypothesis that a 
large amount of aggregate accumulation in the synaptic terminal 
would affect the normal movement of the C. elegans mutants. 
Movement tracking of ctns-1 and ctns-1*α-synuclein mutants 
 As previously stated, the two mutants needed to be observed at 
the same time to correctly compare them. Figure 17 shows an image 
of the mutant strain set up for tracking their movement. The velocity 
data was graphed separately for the mutants, shown in Figure 18. The 
results showed that the ctns-1 average velocity was 
174.79±15.96µm/s and the ctns-1*α-synuclein average velocity was 
121.98±18.30µm/s. This showed a significant difference in the 
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average velocity between the ctns-1 and ctns-1*α-synuclein strains 
(T-test= 0.424, P-value= 0.6759, df= 21). 
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Figure 17: Ctns-1*α-synuclein tracking. Ctns-1 (left) and Ctns-
1*α-synuclein (right) movement tracking experiment. Image captured 
using a Go-3 digital camera on a light microscope at 6.3x 
magnification. 
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 Figure 18: Average velocity comparison graph of Ctns-1 and 
Ctns-1*α-Synuclein C. elegans strains. T-test= 3.6966, P-value= 
0.0013, df=21. Average velocity showing significant difference 
between the strains. Data collected using Image Pro Plus, and a series 
of 120 pictures at 500ms per picture, graphed through Excel. 
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Fluorescent imaging and quantification of ctns-1 and ctns-1*α-
synuclein mutants 
 The images in Figure 19 were used to look for difference in the 
lysosomal membranes between the ctns-1 mutant and ctns-1*α-
synuclein mutant at 630x magnification. The images were similar to 
the fluorescent images of tomm-20, in that I was not able to visualize 
the desired structures, in this case the lysosomal membrane. The 
image did not provide any results between the ctns-1 strain and ctns-
1*α-synuclein strain. 
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   A         B 
 
   C         D 
Figure 19: Ctns-1 fluorescence in C. elegans. Images A-D show 
ctns-1 marker expression. White florescence represents a lysosomal 
cystine transporter. No noticeable difference among the wild type and 
mutant fluorescence. 
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   E         F 
  
   G         H 
Figure 19 continued: Ctns-1 fluorescence in C. elegans. Images 
E-H show ctns-1 marker expression. White florescence represents a 
lysosomal cystine transporter. No noticeable difference among the wild 
type and mutant fluorescence. 
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Discussion 
α-Synuclein has been identified as a possible cause of some forms of 
PD among humans. Although the pathways leading to disease are 
unclear, there is evidence of a variety of mechanisms that could 
contribute. Due to α-synuclein's involvement with synaptic vesicles, it 
can be hypothesized that its misfolding and aggregation affects the 
release of neurotransmitters causing PD. In addition its association 
with high curvature membranes makes synaptic vesicles, 
mitochondria, and lysosomes targets of α-synuclein's dysfunction. The 
disruption of the mitochondrial membrane may result in oxidative 
stress, causing PD. In addition, disruption of the function of lysosomes 
can prevent the removal of aggregate forms of α-synuclein causing PD. 
 The purpose of my research was to examine the various effects 
over-expression of α-synuclein had on several areas of C. elegans to 
better understand it's effects. This was performed first by examining 
the movement of C. elegans among the various mutants over-
expressing α-synuclein. I hypothesized that movement would be 
impacted with the introduction of an over-expression of α-synuclein. 
The second part of this research relied on visual observation of the 
presynaptic terminal in order to make a comparison between the wild 
type worms and the α-synuclein mutants. In this comparison, I 
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hypothesized that there would be disruption in the active zones of the 
presynaptic terminals.  
Movement tracking 
 After recording and graphing the tracking data, there was a 
significant difference in the average velocity of the worms between the 
wild type and α-synuclein strain of both N2 and ctns-1, shown in 
Figures 11 and 18. The movement data in Figures 11 and 18 indicate 
that α-synuclein over-expression is having some impact on their 
movement. This impacted movement may be similar to the loss of 
motor control in PD. Locomotion was quantified in a previous study 
and showed a significant difference between wild type and α-synuclein 
over-expressing C. elegans (Cao, 2010). Since PD symptoms include 
the inability to control motor function, we can infer loss of motor 
control symptom to explain the C. elegans movement in Figure 11 and 
18. The results in Figures 11 and 18 supported my hypothesis; over-
expression of α-synuclein had an effect on their movement. This 
relationship between PD and α-synuclein could also mean an effective 
treatment of PD could start with solving the problems of α-synuclein. 
 The tracking data shown in Figures 12 and 15 did not show any 
significant difference in the average velocity between the wild type and 
α-synuclein strains of both rab-3 and tomm-20. The movement data in 
Figures 12 and 15 opposes my previous movement results as well as 
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my hypothesis that α-synuclein over-expression would result in 
movement differentiation. In a similar experiment tracking the 
trashing of wild type and α-synuclein over-expressing worms; the 
results showed significant difference in thrashing and was interpreted 
as neuronal degeneration (Kuwahara, 2012). My results may be 
caused by a number of factors, including the test or the nature of the 
mutants. A possible reason for this inconsistent data may be from a 
slight variation in the agar gel composition or metal rings used to 
contain the worms in these tests. These two variations may have 
caused the worms to react in an unnatural way and give incorrect 
results when tracked. Another explanation of this data could be the 
presence of greater amounts their food source, E. coli, this would in 
turn change their movement habits in order to eat. The next possibility 
might be that some of the worms ate enough food before being 
transferred to the testing plate while others did not. C. elegans 
typically moves more rapidly when starved, this is because they are 
more desperately in search of food. Another rationale for the lack of 
significant movement difference may be a difference in the average life 
stage of the worm, which could have been accounted for better by 
running a greater number of trials. Another way to better understand 
the effect of the life stage of the worm would be to run trials 
comparing wild type of different ages. Lastly there may have been an 
unknown effect of the mutants and markers used to later visualize 
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internal structures of the worm. Although Figures 12 and 15 show no 
significant difference in average velocity, it appears that Figures 11 
and 18 would be able to confirm some movement difference affecting 
C. elegans due to α-synuclein over-expression. 
Fluorescent microscopy 
 The rab-3 and rab-3*α-synuclein fluorescent images in Figure 13 
show that both the frequency and signal strength of the puncta along 
the axon terminal had decreased in the rab-3*α-synuclein strain 
compared to the rab-3 strain. This supports my hypothesis that α-
synuclein would cause disruption in the presynaptic terminals. In 
Figure 13 there is a clumping of synaptic vesicles caused by the 
misfolding and aggregation of α-synuclein in the α-synuclein mutants. 
Since synaptic vesicles are essential in the transporting and release of 
neurotransmitters, an aggregation like this would hinder their ability to 
perform this task. This shows that α-synuclein is affecting the active 
zone organization which could result in loss of neuron signaling due to 
reduction in neurotransmitter release. The loss of signaling would in 
turn cause the loss of muscular control similar to the symptoms of PD 
patients. This gives possible treatment options to manage PD in 
humans; this data suggests that causing PD patients to produce an 
increased amount of neurotransmitters like the treatments available 
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can help. A less explored way to treat PD may include increasing the 
sensitivity to neurotransmitters in order to alleviate the symptoms. 
 The fluorescent comparison images in both Figure 16 and Figure 
19 are of the tomm-20 and tomm-20*α-synuclein mutants, and the 
ctns-1 and ctns-1*α-synuclein mutants respectively. Both of these 
images did not show their designed cellular structures nor did they 
show any noticeable differences when comparing the marker mutant 
to the α-synuclein mutant. A major reason for this may be the genes 
used to visualize both the mitochondrial membrane and lysosomal 
membrane. If the amount of protein produced by each gene wasn't 
enough to visualize, it may result in the data seen here. The obvious 
way to resolve this problem would be by selecting new genes that can 
be tracked via similar markers. It would first require research into 
more reliably produced products or perhaps genes that produce more 
specific products, so not to mistake various signaling markers. The 
process of constructing the plasmids and creating the mutants would 
remain very much similar, along with the fluorescent microscopy 
procedure. 
Future studies 
 The data gained from this research provides several ways to 
continue to explore α-synuclein. One potential experiment could be to 
expose the created transgenic C. elegans mutants to a mutagen and 
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determine any difference of expression on the synaptic terminals 
afterwards through fluorescent microscopy. This allows continued use 
of constructed mutants to observe the presynaptic terminals. This 
method has been used to discover genes that inhibit transgenic C. 
elegans worms with muscular dystrophy orthologous. Since C. elegans 
experiments can be run on thousands of the worms at once, this gives 
a greater chance that a beneficial mutation may arise and spread 
through the population. Once those healthier worms are identified they 
can be put through the same movement and fluorescent experiments 
to compare the differences from pre mutagen exposed worms. In 
addition, sequencing of the genome may then show the location of 
such inhibitory genes if they arise. 
 Another related area to explore with this research, may involve 
visualizing the effect of α-synuclein on the endoplasmic reticulum (ER). 
This would be an interesting organelle to observe due to its 
responsibilities in protein transporting. In a study involved with IGF in 
C. elegans, the ER is tasked with reducing translation, degrading 
misfolded proteins, and increasing ER-resident chaperones (Henis-
Korenblit, 2009). Since ER stress has been shown to have some effect 
on the folding of proteins, it would make sense it has some 
responsibility in the misfolding and aggregation of α-synuclein. This 
could be experimented with in a similar manner as the synaptic 
vesicles, mitochondria, and lysosomes of this research; through 
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movement tracking and fluorescent comparison of the ER between wild 
type and a newly created mutant.  
 This research helps understanding the role α-synuclein plays in 
PD pathology, the process to fully understand it is to track even more 
systems of eukaryotic cells. Once we can visualize all the differences, 
α-synuclein will be considered a complex protein to be identified and 
examined. The prevention and treatment of PD will be dependent on 
stopping α-synuclein misfolding and aggregation. If α-synuclein 
function can be properly recognized, there is a chance to save the lives 
of millions of affected individuals and the heartaches of their friends 
and family. 
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Methods 
 
Making/Seeding plates for C. elegans 
 First a 5L flask is filled with 3L of ddH2O and a magnetic stir rod 
was added, then a 1L glass bottle is filled with 500mL of ddH2O. Nine 
grams of NaCl, 64 grams of Bacto-Agar, and 7.5 grams of Bacto-
Peptone was added to the flask. The flask is placed into a heat 
resistant plastic container and put into the autoclave along with the 
bottle and transfer tubing, then the autoclave is run on its liquid 
setting for 60 minutes. Once finished the flask is placed on a magnetic 
stirrer for 60-80min and the bottle is stored in a 60oC incubator. After 
the stirring is complete the flask is uncovered and 75mL of 1M KPO4, 
3mL of 1M CaCl2, 3mL of 1M MgSO4, and 3mL of 5mg/mL cholesterol 
in 95% ethyl alcohol is added in that order. The flask is hooked up to a 
dispenser set to 8.5mL for regular plates and 4mL for small plates. The 
plates are then allowed to dry for 48 hours before being ready to be 
seeded with E. coli. A bent glass stir rod was used to spread an OP-50 
strain of E. coli onto the plates, which are then allowed to dry for 24 
hours prior to being used. 
Maintaining C. elegans 
 The C. elegans Bristol strain (N2) originally from Sydney 
Brenner's research was used in these experiments. C. elegans were 
grown at either 15oC or 20oC on agar plates inoculated with  E. coli 
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strain OP50 as their food source following standards set by Brenner in 
1974 (Brenner, 1974). After 3 to 5 days two L4 or adult life stage 
hermaphrodite C. elegans were picked from the latest generation plate 
then transferred to a new inoculated agar plate. 
Freezing C. elegans 
 Brenner's protocol was followed for strain preservation (Brenner 
1974). A freezing solution was made with 18mL of 5M NaCl, 50mL of 
1M KPO4, 300mL of DMSO, and 632mL of ddH2O, the solution was 
autoclaved for 60 minutes. Four C. elegans plates were allowed to run 
out of food simultaneously and are collected into a 15mL conical tube 
by transferring 2mL of M9 solution (70g Na2HPO4, 30g KH2PO4, 5g 
NaCl, and 10g NH4Cl) into each of the plates. The M9 solution, 
containing C. elegans, from each plate was transferred to the tube and 
filled to 15mL with M9 solution. The tube was spun down in a 
centrifuge at speed setting 2 for 2 minutes. Most of the supernatant 
was removed with an automatic liquid vacuum leaving 2.5mL of M9 
along with the C. elegans on the bottom of the tube. Two and a half 
mL of the freezing solution was added and mixed via the pipet and 
1mL aliquots of the solution were added to each of 4 cryovials and 1 
microcentrifuge tube. The vials and microcentrifuge tube are placed 
into a Styrofoam mold and stored in a -70oC freezer. After 1 day, the 
microcentrifuge tube is taken out, thawed, and pipeted onto an 
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inoculated plate to determine C. elegans viability,  the rest of the vials 
can be stored indefinitely until needed.  
Heat shock C. elegans 
 In order to induce the generally hermaphrodite C. elegans 
worms into producing males to allow mutant crossing, heat shocking 
was performed. Following worm handling procedures described by 
Brenner (Brenner, 1974), 15 hermaphrodite L4 life stage worms were 
transferred onto an inoculated plate, this transferring was done 3 more 
times, providing 4 inoculated plates with 15 worms on each. These 
plates are then stored in a dark 25oC incubator for 5 hours, then 
moved to a standard 20oC incubator for 3-4 days or until their 
offspring are present. The plates are observed for males which are 
then mated with their own strain to increase the number of males of a 
particular strain.  
Plasmid creation 
 A PCR mixture was made using 20µL of a 5x Q5 reaction buffer, 
2µL of a 10mM dNTP, .5µL of a 100µM forward and reverse primer for 
the rab-3, tomm-20, or ctns-1, 1µL of a Q5 Hot Start high-fidelity DNA 
polymerase, 1µL of E. coli template DNA and 67µL of D H2O. The PCR 
was run at 98oC for 30 seconds, 17 cycles of 98oC for 10 seconds then 
60oC for 10 seconds then 72oC for 30 seconds, and 72oC for 7 minutes. 
The PCR product was purified with standard DNA mini prep protocol 
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washing through with 45µL of D H2O. The solution was digested by 
adding 1µL of the NheI restriction enzyme and 5µL of buffer solution 2 
and put into a 37oC water bath for an hour. The digested DNA was run 
through gel electrophoresis for one hour at 100 volts, and the 
identified size product was cut out of the gel. The cut out gel was 
melted at 45oC in 1mL of ADB buffer for 5 minutes and was run 
through standard DNA mini prep protocol, washing through with 20µL 
of D H2O. Three µL of the solution was mixed with .5µL of a vector for 
mCherry, red fluorescent protein, and NheI, 1.5 µL of D H2O, and 5 µL 
of a ligase mixture. After a 35 minute incubation at 15oC; 5 µL was 
added to competent E. coli and put on ice for 15 minutes, a 42OC 
water bath for 90 seconds, and back on ice for 5 minutes. Then the 
solution was put into 1mL of liquid broth and placed in a 37oC 
incubator for 40 minutes and centrifuged; 100µL and the bacterial 
pellet was left and spread across an agar plate containing ampicillin 
and incubated at 37oC for 24 hours. The isolated colonies were 
transferred into a 2.5mL tube of LB containing 5µL of ampicillin and 
was incubated in a 37oC shaker for 24 hours. A plasmid mini prep was 
performed on the E. coli cultures and digested with NheI, the solution 
was run through gel electrophoresis, a correct size product was found 
and that plasmid was chosen for integration. 
Integration of plasmid into C. elegans 
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 C. elegans mutants were made by injecting the constructed 
plasmids, rab-3, tomm-20, and ctns-1, into the gonads of 
hermaphrodite worms. This caused the presence of an extra 
chromosomal array in the genome, marked by GFP, green fluorescent 
protein. The uptake of the extra chromosomal array was performed by 
the UV/trimethyl psolaren method (Gengyo-Ando, 2000). Integration 
was confirmed by presence of the marker in 100% of F3 generation. 
Mating C. elegans 
 The GFP tagged Rab-3 strain, 1 L4 life stage hermaphrodite was 
picked onto a small agar plate along with 7 to 10 adult males of the 
mCherry, red fluorescent protein, tagged α-synuclein strain. Successful 
mating was noted by observing half of the worms to be 
hermaphrodites and half to be males. Ten L3 life stage hermaphrodite 
worms were picked individually onto small inoculated agar plates from 
the F1 generation of the mating. The F2 generation was observed 
under a florescent microscope and 10 to 20 hermaphrodite worms 
containing both the green fluorescent protein (GFP) and mCherry 
marker was picked individually onto small inoculated agar plates. 
Finally to ensure double mutant strain, the F3 generation was 
observed under a florescent microscope and needed to show that all 
the worms on the plate have both markers. This procedure was done 
similarly for both the GFP tagged Tomm-20 strain with the α-synuclein 
strain and the GFP tagged Ctns-1 strain with the α-synuclein strain. 
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Out-crossing C. elegans 
 Removal of the mCherry tagged α-synuclein strain from the Rab-
3*α-synuclein double mutant strain was performed by first mating with 
N2 strain males. Ten L3 life stage hermaphrodites were picked 
individually onto small inoculated agar plates. The F2 generation was 
observed under a fluorescent microscope and 20 hermaphrodite 
worms containing the mCherry marker on the rab-3, tomm-20, and 
ctns-1 strain were picked individually onto small inoculated agar 
plates. The F3 generation was observed under a florescent microscope 
to ensure complete out-crossing of the mutant strain by seeing all the 
worms with only the mCherry marker.  
C. elegans imaging and tracking 
 The rab-3, tomm-20, and ctns-1 strains were compared against 
the strains over-expressing α-synuclein. They were imaged on a light 
microscope using a Go-3 digital camera. In order to track the 
movement of the worms two metal rings were heated and placed side 
by side onto a non seeded agar plate, then 10 to 13 worms from each 
mutant were separated into their own ring on the plate, as seen in 
Figure 9. As little E. coli as possible was used to transfer the worms 
onto the plate with the rings; this was to reduce the influence food had 
on any movement of the worms. The plate was then put under a light 
microscope with a Go-3 digital camera that rapidly took a series of 
photographs of the worms using Image Pro; which was used again in 
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order to track the movement of the worms of one mutant at a time 
and was graphed using Excel. 
 
  
63 
	  
 
Figure 20: Sample of tracking experiment. N2 (right) and N2*α-
synuclein (left) movement tracking experiment. Red arrows indicate an 
example of movement in between the next picture being taken. Image 
captured using a Go-3 digital camera on a light microscope at 6.3x 
magnification. 
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Mounting C. elegans 
 Standard mounting procedure from Shaham was followed 
(Shaham, 2006), with altered worm transferring steps. 50 L4 life stage 
hermaphrodite C. elegans were picked onto a cover slip containing 
15µL of 6M Levamisole, a worm paralyzing solution, causing better 
worm orientation. The worms then sat in the paralyzing solution for 10 
minutes before a microscope slide with the agar pad was placed onto 
the cover slip. Nail polish was placed on the corners of the coverslip to 
cause adhesion to the slide and allowed to dry. 
Fluorescent microscopy of C. elegans 
 The mounted worms were imaged with Zeiss AxioObserver 
microscope, containing a fluorescent light source. Metamorph 7.6 was 
used to process the images. The images were taken observing the 
axon and cell body region of the C. elegans mutants. 
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